Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04290039 · ClinicalTrials.gov registry record · Phase 1
Sublingual vs IV Atropine Bioavailability Study
A Phase 1 study, sponsored by Biomedical Advanced Research and Development Authority.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04290039 is a Phase 1 study that has completed, run by Biomedical Advanced Research and Development Authority. The registered enrollment target is 15 participants.
The verdict
NCT04290039, a Phase 1 study, has completed, sponsored by Biomedical Advanced Research and Development Authority.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This randomized, three-sequence, three-period, phase 1 study is designed to assess the bioavailability and pharmacokinetics (PK) of sublingually administered atropine sulfate ophthalmic solution 1% USP (at 0.5 mg and 1.0 mg; test) compared to atropine sulfate injection administered IV (1.0 mg; reference).
Interventions
- DRUG Atropine Sulfate Ophthalmic Solution
- DRUG Atropine Sulphate Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-01-04 |
| Est. Completion | 2020-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04290039
The ClinicalTrials.gov registry entry for NCT04290039 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomedical Advanced Research and Development Authority, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atropine Sulfate Ophthalmic Solution is the first listed.
NCT04290039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04290039 about?
NCT04290039 is a clinical study titled "Sublingual vs IV Atropine Bioavailability Study". This randomized, three-sequence, three-period, phase 1 study is designed to assess the bioavailability and pharmacokinetics (PK) of sublingually administered atropine sulfate ophthalmic solution 1% USP (at 0.5 mg and 1.0 mg; test) compared to atropine sulfate injection administered IV (1.0 mg; refer...
What is the current status of trial NCT04290039?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2020-01-04. Estimated completion is 2020-02-08.
What interventions are being tested in trial NCT04290039?
The interventions under investigation include: Atropine Sulfate Ophthalmic Solution (DRUG), Atropine Sulphate Injection (DRUG).
Who is sponsoring clinical trial NCT04290039?
This trial is sponsored by Biomedical Advanced Research and Development Authority, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.